MegaBanner-Right

MegaBanner-Left

LeaderBoad-Right

LeaderBoard-Left

Home » Featured IND » R18m donation boosts African-centric medicine research

R18m donation boosts African-centric medicine research

An R18m donation from an alumnus will go towards research into African-centric medicines for infectious diseases at the University of Cape Town (UCT) Drug Discovery and Development Centre, H3D.

The donation will be used to establish an initial five-year Neville Isdell (former chairman and CEO of Coca Cola and UCT graduate) Chair in African-centric Drug Discovery and Development at H3D. The centre’s director and founder, Professor Kelly Chibale, will hold the chair, which includes the directorship of H3D.

“I am excited about playing a part in helping to achieve African solutions to public health challenges on the continent and across the world. I hope this support will help Professor Chibale to drive and lead innovative research and development (R&D) of new malaria medicines, as well as new tuberculosis and antimicrobial resistance treatments, and train a new generation of African scientists with key modern pharmaceutical skills required to discover modern medicines,” said Isdell.

The donation will be used partly to lead efforts in establishing the H3D African Drug Metabolism and Disposition Project, also known as the H3D African Liver Project. This project will focus on addressing the issue of variability in drug response across African populations, which is mostly driven by genetic differences in the expression and activity of drug metabolising enzymes.

Chibale said the aim was to develop and validate a preclinical discovery tool that can be used to prioritise drug candidates during their chemical lead optimisation phase based on the predicted pharmacological profile in African patients.

“In addition to providing useful data for targeted clinical trial design, and eventually for the establishment of better directed drug dosage and dosage intervals, the African Liver Project will also make H3D a unique centre of excellence where scientists from the Global North and Africa will work hand in hand to better understand genetic variability in diverse African populations,” said Chibale.

H3D already has a potential drug for malaria in human trials. The potent anti-malarial clinical development candidate has the potential to cure, block transmission and protect in a single dose. The H3D portfolio also includes projects targeting tuberculosis drug discovery and is expanding to address the serious threat of antimicrobial resistance, in part driven by hospital infections resistant to conventional antibiotics.

Chibale said the funding would be put to extremely good use at H3D, which was launched eight years ago, and has grown from a staff of four scientists to 60.

“H3D will need sustainable funding at critical mass if it is to succeed. Should H3D continue to be successful, it could result in the beginning of a home-grown pharmaceutical R&D industry that would focus on the unmet medical needs of African populations and create high skilled jobs for African scientists.”

To enquire about Cape Business News' digital marketing options please contact sales@cbn.co.za

Related articles

Steinmüller Africa invests in education at two Mpumalanga schools 

Continuing its commitment to uplifting local communities, Steinmüller Africa is improving schools in Evander and eMalahleni, Mpumalanga. Equipment and renovations have been donated to...

De Beers donates former diamond sorting and sales office in Kimberley to Sol Plaatje University

De Beers Group have announced that it is donating the Harry Oppenheimer House (HOH) building in Kimberley to the Sol Plaatje University following the...

MUST READ

Strategic co-location of IFAT Africa and analytica Lab Africa to boost...

IFAT Africa and analytica Lab Africa will be co-located at the Gallagher Convention Centre this year to optimise the synergies across the laboratories, science...

RECOMMENDED

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.